Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study
| Autor: | Nobuki, Furubayashi, Futoshi, Morokuma, Toshihisa, Tomoda, Yoshifumi, Hori, Takahito, Negishi, Akihiro, Miura, Hiroki, Komori, Kentaro, Kuroiwa, Motonobu, Nakamura |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Aged
80 and over Male Cancer Research Time Factors Drug Substitution Carcinoma General Medicine Middle Aged Antibodies Monoclonal Humanized Risk Assessment Treatment Outcome Japan Urinary Bladder Neoplasms Oncology Risk Factors Antineoplastic Combined Chemotherapy Protocols Humans Female Immune Checkpoint Inhibitors Aged Retrospective Studies |
| Zdroj: | Anticancer Research. 42:1571-1577 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.15631 |
| Popis: | The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear.Thirty-four patients who received pembrolizumab as second-line treatment after first-line platinum-based chemotherapy were retrospectively evaluated.According to overall survival (OS) from pembrolizumab, there was a significant difference between ≤4 and4 prior chemotherapy cycles (7.0 and 25.5 months, p=0.034), but not between ≤6 and6 cycles (11.3 and 6.6 months, p=0.658). According to the Cox proportional hazards regression model, the number of chemotherapy cycles was not correlated with better OS in pembrolizumab-treated patients. According to the OS from the first-line treatment, there was a significant difference between ≤4 and4 prior chemotherapy cycles (17.3 and 37.1 months, p0.001), but not between ≤6 and6 cycles (18.6 and 27.3 months, p=0.276).The optimal timing of switching from platinum-base chemotherapy to pembrolizumab in advanced UC is around six cycles. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|